My IDSA Contact Us
IDSA NewsPrint-Friendly Newsletter
Forward to a Friend
Search Back Issues
 
Education & Training Resources Practice Guidelines Journals & Publications Policy & Advocacy Meetings About IDSA
February 2009
Volume 19 Issue 2
Policy and Advocacy
Advocacy Update: IDSA Expresses Concern About State Lyme Disease Bills

IDSA recently sent letters to legislators in several states expressing the Society’s concern over bills that would promote long-term antibiotic therapy in treating Lyme disease, despite medical and scientific evidence indicating that such treatment may do more harm than good.  A Connecticut bill would prohibit state licensing boards from disciplining physicians who prescribe such treatment. Bills in New York, Vermont, and West Virginia would mandate insurance coverage of such treatments. Long-term antibiotic therapy is not medically indicated for Lyme disease, and it can lead to potentially fatal infections of the bloodstream, as a result of intravenous administration. It can also promote the development of drug resistance among other microorganisms.

Other advocacy efforts include:

IDSA opposed an Indiana bill (House bill 1567) that would ban the administration of influenza vaccines containing thimerosal in pregnant women and young children.  The Society addressed its concerns in a letter to the Indiana House of Representatives Committee of Public Health asserting that the bill is based on flawed pseudoscience linking thimerosal in vaccines to adverse effects on children. A Feb. 12 ruling by the Special Masters of the U.S. Court of Federal Claims reaffirmed that thimerosal-containing vaccines were not causal factors in the development of autism or autism spectrum disorders.

IDSA sent comments to the Centers for Medicare and Medicaid Services in support of a gain-sharing exception that would allow infection control practitioners to share in the savings they help generate in hospitals, therefore incentivizing infection control strategies.
How useful is this article?

< Previous Article | Next Article >

Post a comment

Your name:

Your comment:


Top Stories
Candidiasis Guidelines Updated
IDSA Journal Club
From the President
Vaccine Science Prevails
Patient Care and Science
EIN Considers Alternatives to Acyclovir During Shortage
Updated Rotavirus Recommendations Include New Vaccine
ACIP Changes Recommendations for Anthrax, Hepatitis A Vaccines
Drug Approvals, Recalls, Adverse Events Update
Practice Management
CMS Sending Clinicians Reports on their Medicare Costs
How to Put Health IT to Work in Your Practice
Policy and Advocacy
Federal HAI Prevention Plan is “Important First Step”
Stimulus Funding May Go Toward ID Research, HIV/AIDS Prevention
HIVMA Urges Medicare to Cover Treatment of Facial Lipodystrophy
Advocacy Update: IDSA Expresses Concern About State Lyme Disease Bills
Education and Training
SHEA Offers California Epidemiology Course
You and Your Colleagues
Welcome New IDSA Members!

IDSA | 1300 Wilson Blvd., Suite 300 | Arlington, VA 22209 | Phone: (703) 299-0200
To ensure delivery, please add 'idsa@idsociety.org' to your email address book or Safe Sender List.
If you are still having problems receiving our communications,
see our white-listing page for more details.